SynthesisAnnals of surgical oncology2025
Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.
Synthesis in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Small bowel obstruction from metastatic small intestinal neuroendocrine tumor managed solely with somatostatin analog.JCEM case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic neuroendocrine tumors (PNETs) are a rare type of pancreatic cancer. Surgical resection is the primary curative treatment option, but whether this is the optimal treatment remains debatable. To address this question, we compared surgical versus nonsurgical management of PNETs. PATIENTS AND
methodsWe searched the Medline (via PubMed), Scopus, Web of Science, and Embase databases through the end of 2023. Studies that compared surgical and nonsurgical interventions for PNETs across all grades, stages, and sizes and that reported survival outcomes were included. The primary endpoint was overall survival. The meta-analysis was performed using STATA software.
resultsSeventy-seven articles (including 62 654 patients) were included in the final analysis. The pooled hazard ratio (HR) for mortality of surgical versus nonsurgical management was 0.30 (95% confidence interval [CI], 0.26-0.34; P < 0.001). Compared with nonsurgical management, surgical management was associated with better 1-year (94% vs. 78%), 3-year (85% vs. 57%), 5-year (77% vs. 46%), and 10-year (64% vs. 34%) survival. Pooled HRs for the mortality of patients who underwent surgery versus nonsurgical management for functional, nonfunctional, low grade (G1/G2), small (< 2 cm), and metastatic/locally advanced PNETs were 0.30, 0.30, 0.31, 0.26, and 0.33 respectively (P < 0.001). Surgical management of small PNETs (< 1 cm) showed comparable survival rates between surgical and nonsurgical approaches.
conclusionsSurgical PNET management had better outcomes than nonsurgical PNET management and should be considered the primary treatment option for resectable PNETs, However, nonsurgical management may be a reasonable option for select patients with small (<1 cm), asymptomatic PNETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.